Prognostic value of serum vascular endothelial growth factor in Egyptian females with metastatic triple negative breast cancer

摘要: Abstract Objectives The aim of this work was to explore the value serum vascular endothelial growth factor-A (VEGF-A) in patients with metastatic triple negative breast cancer (TNBC) treated chemotherapy. primary end point overall survival (OS). Secondary points were response rate (RR), progression-free (PFS) and VEGF-A level at baseline, mid-therapy therapy. Design methods Female aged 18 years or above histologically proven TNBC included. Serum VEFG-A levels measured after 3rd 6th cycles FAC chemotherapy regimen (Fluorourcil, Adriamycin, Cyclophamide). Results RR 57%. median PFS OS 7 11.2 months, respectively (95% CI: 4.3–9.7 3.8–18.5 months, respectively). Patients whose disease progressed despite therapy had a significantly higher baseline than those who did not progress. drop continuation high lower but low levels. Conclusion outcome is poor regimen. Alternative chemotherapeutic regimens novel therapeutic approaches including targeting VEGF and/or its receptors are warranted.